Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer

Gregory J. Riely; Egbert F. Smit; Myung‐Ju Ahn; Enriqueta Felip; Suresh S. Ramalingam; Anne S. Tsao; Melissa L. Johnson; Francesco Gelsomino; Raymond Esper; Ernest Nadal; Michael Offin; Mariano Provencio; Jeffrey Clarke; Maen Hussain; Gregory A. Otterson; Ibiayi Dagogo‐Jack; Jonathan W. Goldman; Daniel Morgensztern; Ann Alcasid; Tiziana Usari; Paul Wissel; Keith D. Wilner; Nazima Pathan; Svitlana Tonkovyd; Bruce E. Johnson

doi:10.1200/jco.23.00774

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

For patients with treatment-naïve and previously treated BRAFV600E-mutant metastatic NSCLC, encorafenib plus binimetinib showed a meaningful clinical benefit with a safety profile consistent with that observed in the approved indication in melanoma.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Riely et al. (2023) studied this question.

synapsesocial.com/papers/69d76859aa68b335b4f31543 https://doi.org/10.1200/jco.23.00774

View Full Paper

Ask AI

Bookmark

Share

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading